Literature DB >> 19414491

Short- and long-term outcomes of surgery for active infective endocarditis: a Tunisian experience.

Sofiene Rekik1, Imen Trabelsi, Imed Maaloul, Mourad Hentati, Adnane Hammami, Imed Frikha, Mounir Ben Jemaa, Samir Kammoun.   

Abstract

From January 1997 to December 2006, all patients with a Duke criteria-based definite diagnosis of infective endocarditis (IE) operated on during the active phase in a Tunisian high volume tertiary-care centre were included. Among the 186 patients with IE identified during the study period, 88 (48.35%) required surgery in the active phase. Mean age was 34.9 years, 54 (61.4%) were men. The infected valve was native in 70 cases (79.5%) and prosthetic in 18 (20.5%). Streptococcus sp. were the most common causative microorganisms. The most frequent indication for operation was congestive heart failure. There were 24 in-hospital deaths (27.27% early mortality). By multivariate analysis, severe congestive heart failure (HR=13.82, 95% CI [3.38-38.15], P<0.001) and large >15 mm vegetations (HR=6.02, 95% CI [1.48-18.52], P=0.03) were predictive of in-hospital mortality. Survivors were followed-up from 3 to 120 months, mean of 28.6. Actuarial 5- and 10-year survivals free from the combined endpoint of recurrent IE, cardiovascular death and late surgery in survivors were 69+/-5% and 63+/-7%, respectively. In conclusion, despite medical progress, surgery for endocarditis in Tunisia remains challenging and yields high mortality rates. Severe heart failure is the most powerful predictor of mortality. Long-term outcome is, however, satisfactory.

Entities:  

Mesh:

Year:  2009        PMID: 19414491     DOI: 10.1510/icvts.2008.197715

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  1 in total

Review 1.  A narrative review of early surgery versus conventional treatment for infective endocarditis: do we have an answer?

Authors:  Umberto Benedetto; Cristiano Spadaccio; Federico Gentile; Marc R Moon; Francesco Nappi
Journal:  Ann Transl Med       Date:  2020-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.